The American Cancer Society (ACS) l...

The American Cancer Society (ACS) lately published updated recommendations (1) for the early detection of cervical cancer; this topic was last reviewed in 1987 The guidelines are based upon a literature review combined with person specially versed opinion when sufficient evidence was not available. In an effort to build consensus, several professional clusters also were provided an opportunity to review and endorse these guidelines.

The ACS guidelines move a movement toward less exces screening and incorporation of emerging technologies when clinically feasible. The accompanying table upon page 1678 compares the ACS guidelines with the U Preventive Services Task Force (USPSTF) recommendations (2) that appear in this issue of American Family Physician. The USPSTF eagerly endorses the use of Papanicolaou (Pap) smears to bring to light premalignant and malignant lesions. It reaffirms cessation of screening at 65 years of age, commits against Pap screening among women who have had hysterectomies for benign conditions, and in contrast with the ACS, closes that there is insufficient evidence to assess the use of of the present day technologies (e.g., thin-layer cytology, computerized screening, human papillomavirus [HPV] testing).

Advances in understanding the natural history of HPV infection and cervical cancer biology have revealed that HPV infections generally are transient. Among high-risk HPV subtype 70 percent of infections regres within sum of two units years, (3) suggesting that les aggressive testing among younger women will allow for the spontaneous regression of HPV-associated abnormalities before screening is initiated.

The updated ACS guideline states that women above age 70 who have had three consecutive negative Pap proofs over the prior 10 years may discontinue screening. As noted in the guideline, the decision mandates a discussion regarding the risks, benefits, and limitations of screening, as well as clinical discernment regarding other factors in a patient's medical history.

Although lacking in proven efficacy, vaginal slap smears after hysterectomy for benign conditions appear to be a customary clinical practice, accounting for untold medical require to be paid [i]or[/i] undergones and patient discomfort. The ACS guideline commends against vaginal cytology testing after total hysterectomy for benign conditions when sufficient documentation is available. Women who have undergone a subtotal hysterectomy should continue standard cervical cancer screening. Patients with a history of cervical intraepithelial neoplasia grade 2 or 3 (CIN 2/3) and patients for whom it is not possible to document the absence of CIN 2/3 should be guarded until three documented, consecutive, technically satisfactory normal/ negative cervical cytology proofs are achieved within 10 years.

The ACS guideline also approves that testing should be performed annually with conventional cervical cytology or each two years with liquid-based cytology, owing to the greater sensitivity of liquid-based touchstones At or after age 30 women who have had three consecutive, technically satisfactory, normal/negative touchstones may be screened every brace to three years unless there is a clinical contraindication to this approach. A history of normal/negative cytologic follows has been shown to have a protective issue on cervical cancer incidence, (45) probably as a inference of the detection and treatment of various premalignant cervical lesions. Although many published studies examining liquid-based Pap technology appear to have more [i]or[/i] less methodologic flaws, this test is an acceptable option for cervical cancer screening. Liquid-based Pap exhibitions and conventional cytology yield similar percentages of satisfactory specimens. (6)

Although the U fodder and Drug Administration (FDA) has not approved HPV DNA testing for primary cervical cancer screening, this technology appears to be a promising adjunct to cytologic testing. The ACS guideline states that if the FDA approves HPV DNA testing (in combination with cytology) for cervical cancer screening, it is reasonable in women aged 30 years and older to perform cervical cancer screening each three years with conventional or liquid-based cytology in combination with a standard for DNA from high-risk HPV subtype Combined cytology and HPV DNA testing should not be performed more frequently than every three years. Counseling and educating patients about the risks of HPV infection remains a priority. The recommendation to restrict HPV testing to women age 30 and older would resolve into the number of women referr for colposcopy because of transient HPV infection.

The ACS guideline also provides relevant recommendations for collecting cervical specimens, including use of an extended-tip spatula to sample the ectocervix and the transformation region and use of an endocervical brush (rather than a swab) to garner endocervical cells and high transformation belt specimens. Alternatively, a single sample device, of the like kind as the cervical broom, can be used to simultaneously sample the endocervix and transformation zone